Dave Reena, O'Brart David P S, Wagh Vijay K, Lim Wei S, Patel Parul, Lee Jennifer, Marshall John
From the Keratoconus Research Institute, Department of Ophthalmology, St. Thomas' Hospital, London, United Kingdom.
From the Keratoconus Research Institute, Department of Ophthalmology, St. Thomas' Hospital, London, United Kingdom.
J Cataract Refract Surg. 2016 May;42(5):717-24. doi: 10.1016/j.jcrs.2016.03.028.
To assess the long-term efficacy and safety of hyperopic laser in situ keratomileusis (LASIK).
Department of Ophthalmology, St. Thomas' Hospital, London, United Kingdom.
Prospective cohort study.
Hyperopic LASIK was performed using a mechanical microkeratome, an optical zone of 6.5 mm, and a blend zone of 1.5 mm. Simple hyperopia was treated.
The mean patient age was 51.6 years (range 34 to 60 years). Preoperatively, the mean spherical equivalent (SE) was +3.74 diopters (D) (range +1.25 to +6.50 D). The mean attempted correction was +3.64 D (range +1.5 to +6.0 D). The mean follow-up was 16.5 years. The mean SE was +0.28 D (range -1.0 to +1.5 D) at 12 months, +0.84 D (range -0.75 to +3.35 D) at 5 years, and +1.74 D (range -0.75 to +4.13 D) at 16 years, representing an increase in hyperopia of +1.47 D ± 1.43 (SD) between 1 year and 16 years (P < .0001) and of +1.13 ± 0.8 D between 5 years and 16 years (P < .03). The uncorrected distance visual acuity improved at 16 years (P < .0001); corrected distance visual acuity (CDVA) was unchanged (P < .2). The efficacy index was 0.5 and the safety index, 1.09. One eye (3%) lost 2 lines of CDVA. Keratometry remained stable between 1 year and 16 years (P < 1.0). Four eyes (12%) had cataract surgery, and 2 (6%) had laser iridotomy. There was no ectasia.
After hyperopic LASIK, an increase in hyperopia occurred between 1 and 5 years and 16 years. At 16 years, efficacy was limited but with no sight-threatening complications.
Dr. Marshall was a consultant to Summit Technology, Inc. Dr. O'Brart holds a noncommercial research grant from Alcon Laboratories, Inc. None of the other authors has a financial or proprietary interest in any material or method mentioned.
评估远视性准分子原位角膜磨镶术（LASIK）的长期疗效和安全性。
英国伦敦圣托马斯医院眼科。
前瞻性队列研究。
使用机械微型角膜刀进行远视性LASIK手术，光学区为6.5毫米，混合区为1.5毫米。治疗单纯性远视。
患者平均年龄为51.6岁（范围34至60岁）。术前，平均等效球镜度（SE）为+3.74屈光度（D）（范围+1.25至+6.50 D）。平均预期矫正量为+3.64 D（范围+1.5至+6.0 D）。平均随访时间为16.5年。术后12个月时平均SE为+0.28 D（范围-1.0至+1.5 D），5年时为+0.84 D（范围-0.75至+3.35 D），16年时为+1.74 D（范围-0.75至+4.13 D），这表明1年至16年之间远视增加了+1.47 D±1.43（标准差）（P <.0001），5年至16年之间增加了+1.13±0.8 D（P <.03）。16年时未矫正远视力有所改善（P <.0001）；矫正远视力（CDVA）无变化（P <.2）。疗效指数为0.5，安全指数为1.09。一只眼（3%）的CDVA下降了2行。角膜曲率在1年至16年之间保持稳定（P <1.0）。4只眼（12%）接受了白内障手术，2只眼（6%）接受了激光虹膜切开术。未发生角膜扩张。
远视性LASIK术后，1至5年以及16年时远视度数增加。16年时，疗效有限，但未出现威胁视力的并发症。
马歇尔博士是Summit Technology公司的顾问。奥布拉特博士持有爱尔康实验室公司的非商业研究资助。其他作者均未对文中提及的任何材料或方法拥有财务或专利权益。
